Abstract:This study involves a comparative antidiabetic evaluation, antioxidant and anti‐tubercular evaluation of quinoline‐pyrazopyrimidines and their simple quinoline‐4‐arylamine analogues. The incorporation of pyrazopyrimidine ring to quinoline generally lowers the antidiabetic, antioxidant and antitubercular activity. The molecular docking simulations further discloses these compounds to be the allosteric inhibitors of the α‐glucosidase. Two libraries of quinoline‐based hybrids 1‐(7‐chloroquinolin‐4‐yl)‐1H‐pyrazolo[3,4–d]pyrimidin‐4‐amine and 7‐chloro‐N‐phenylquinolin‐4‐amine were synthesized and evaluated for their α‐glucosidase inhibitory and antioxidant properties. Compounds with 4‐methylpiperidine and para‐trifluoromethoxy groups, respectively, showed the most promising α‐glucosidase inhibition activity with IC50=46.70 and 40.84 μM, compared to the reference inhibitor, acarbose (IC50=51.73 μM). Structure‐activity relationship analysis suggested that the cyclic secondary amine pendants and para‐phenyl substituents account for the variable enzyme inhibition. Antioxidant profiling further revealed that compounds with an N‐methylpiperazine and N‐ethylpiperazine ring, respectively, have good DPPH scavenging abilities with IC50=0.18, 0.58 and 0.93 mM, as compared to ascorbic acid (IC50=0.05 mM), while the best DPPH scavenger is NO2‐substituted compound (IC50=0.08 mM). Also, compound with N‐(2‐hydroxyethyl)piperazine moiety emerged as the best NO radical scavenger with IC50=0.28 mM. Molecular docking studies showed that the present compounds are orthosteric inhibitors with their quinoline, pyrimidine, and 4‐amino units as crucial pharmacophores furnishing α‐glucosidase binding at the catalytic site. Taken together, these compounds exhibit dual potentials; i. e., potent α‐glucosidase inhibitors and excellent free radical scavengers. Hence, they may serve as structural templates in the search for agents to manage Type 2 diabetes mellitus. Finally, in preliminary assays investigating the anti‐tubercular potential of these compounds, two pyrazolopyrimidine series compounds and a 7‐chloro‐N‐phenylquinolin‐4‐amine hybrid showed sub‐10 μM whole‐cell activities against Mycobacterium tuberculosis.

Synthesis and biological evaluation of 3‐hydroxypyrazoles as aquaporin 9 inhibitors

Synthesis, Crystal Structures, Fluorescence and Xanthine Oxidase Inhibitory Activity of Pyrazole-Based 1,3,4-Oxadiazole Derivatives

Synthesis, In Vivo, ADME Determination, and Molecular Docking Studies of 1,3,4‐Oxadiazoles Containing Pyridine and Piperazine Moieties as New Diuretic Agents

Exploration of 1,3,5-trisubstituted pyrazoline derivatives as human carbonic anhydrase inhibitors: Synthesis, biological evaluation and in silico studies

Design, Synthesis, Biological Evaluation and Molecular Modeling of Novel 1H-Pyrazolo[3,4-d]pyrimidine Derivatives As BRAF(V600E) and VEGFR-2 Dual Inhibitors

Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Pyrimidine Derivatives as Potential Calcium Channel Blockers

In Silico Analysis, Synthesis, and Biological Evaluation of Triazole Derivatives as H1 Receptor Antagonist

Synthesis,Antidiabetic and Antitubercular Evaluation of Quinoline–pyrazolopyrimidine hybrids and Quinoline‐4‐Arylamines

A new framework for novel analogues of pazopanib as potent and selective human carbonic anhydrase inhibitors: Design, repurposing rational, synthesis, crystallographic, in vivo and in vitro biological assessments

Synthesis and Biological Evaluation of Carbonic Anhydrase III and IX Inhibitors using Gas Chromatography with Modified pH Sensitive Pellets

Pyridazine Derivatives: Molecular Docking, ADMET Prediction, and Synthesis for Antihypertensive Activity

Design, Synthesis and Biological Evaluation of Novel 5-Methyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole Derivatives As Potent Potassium-Competitive Acid Blockers.

Synthesis and evaluation of 3-(phenylethynyl)-1,1′-biphenyl-2-carboxylate derivatives as new HIF-1 inhibitors

Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors

Design, Synthesis and Biological Evaluation of New Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors.

Inhibitors of Mammalian Aquaporin Water Channels

Synthesis of 2,4-dihydroxyacetophenone derivatives as potent PDE-1 and -3 inhibitors: in vitro and in silico insights

In‐vitro and in‐silico investigations of SLC‐0111 hydrazinyl analogs as human carbonic anhydrase I, II, IX, and XII inhibitors

Design, Synthesis And Biological Evaluation Of Benzohydrazide Derivatives Containing Dihydropyrazoles As Potential Egfr Kinase Inhibitors

Synthesis, In vivo, and In silico Evaluation of New Pyrazoline‐ Benzothiazole Conjugates as Orally Administered Antiepileptic Agents

Synthesis, molecular modelling, and biological evaluation of novel quinoxaline derivatives for treating type II diabetes